Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPIT: Sublingual Immunotherapy in Allergic Rhinoconjunctivitis
NCT00550875Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jun 2007
- Primary completion
- Dec 2009
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of lolium perenne + cynodon dactylon in allergic rhinoconjunctivitis (ARC), sponsored by LETI Pharma. Started Jun 2007; status: completed.
02
Drugs
lolium perenne + cynodon dactylon
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00550875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550875.